A double-blind study of the effects of isosorbide dinitrate, 10 mg given orally four times a day, propranolol, 40 mg four times a day, and the combination of these two drugs was performed on 21 patients with angina pectoris. Each patient received placebo, isosorbide, propranolol, and the combination of the two drugs for 1 month each in a random sequence over 4 months. The number of anginal pains and nitroglycerin tablets used were recorded, and a multistage treadmill ECG exercise test was performed after each treatment period.
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Treadmill exercise Heart rate ST segment Nitroglycerin C ORONARY heart disease commonly presents as angina pectoris. The chest pain probably occurs when the myocardial oxygen demands exceed the oxygen that can be supplied by the diseased coronary arteries. From 
Treatment Procedures
This prospective, double-blind study was carried out in a crossover fashion. The treatment periods were divided into four inonthly periods of treatment in which the subjects took: (I) placebo and placebo (PLAC); (II) isosorbide dinitrate by mouth, 10 mg four times daily, and placebo (ISO); (III) propranolol 40 mg by mouth four times daily and placebo (PROPRA); and (IV) the combination of propranolol and isosorbide dinitrate (COMB) . The tablets were given to the patients in numbered bottles coded by a research Table 1 Characteristics of 21 pharmacist. The treatments were given in a random time sequence. The dose of isosorbide dinitrate of 10 mg four times a day was selected because that was the dose used by previous investigators2 who reported beneficial results. Each patient was asked to keep a log of the number of anginal pains experienced and the number of nitroglycerin tablets consumed. At the end of each monthly period the patient was examined by one of the investigators, and his log of chest pains and nitroglycelin tablets was recorded. A 12-lead resting ECG was obtained prior to each exercise test.
Exercise Studies A multistage treadmill test3 was used in the objective evaluation of the efficacy of each treatment. Each patient performed the treadmill test at least two times on different days before being included in the study, and therefore, the patients were thoroughly familiar with the testing procedure. Exercise on the treadmill was continuous and consisted of 3-min stages of gradually increasing speed and grade. The patients exercised to the level of established anginal pain and were asked to perform to the same level of pain in each subsequent exercise study. Endurance time was defined as the duration of exercise on the treadmill. Electrocardiographic monitoring and recording were performed with a minor modification of the precordial electrocardiogram described by Abarquez and associates.4 From the two previous exercise tests the lead which showed the maximal ST-segment depression was selected and used throughout the study. Resting heart rate was determined just before the exercise from the electrocardiogram after 5 min in the standing position. Blood pressures at rest, during each stage of exercise, and in the recovery period were obtained with a mercury sphygomomanometer by the cuff method. As a rough index of the myocardial oxygen demands, the product of maximal heart rate and systolic blood pressure during exercise was determined in each subject. 5 The heart rate response to a Valsalva maneuver (blowing against a closed sphygmomanometer to maintain 40 mm Hg pressure for 15 sec) was determined in each visit before the treadmill test. The Valsalva ratio6 (the longest R-R cycle divided by the shortest R-R cycle after the strain) was calculated to estimate the effects of the treatments on the heart rate response (mediated by the autonomic nervous system) to the Valsalva maneuver.
Exercise studies were interpreted independently by two of us (A.N.G. and J.F.M.). In our laboratory, interobserver variation was found to be small; in a previous study, disagreements occurred in six of 91 cases. 7 The maximal STCirculation, Volume 1] , where x is an observed value), significant interaction was eliminated and, in addition, the transformation appeared to have stabilized the variances. Therefore, the transformed data were used in analyzing the abovementioned variables.
Time Sequence
To investigate the possibility that the order in which the treatments were given had any effect on the results observed, the data were placed in chronologic order rather than by treatments, and analyses of variance were performed. No F ratios were significant; thus these tests failed to reveal any indication that the results were related to the time sequence in which the treatments were given.
Results
Anginal Pains and Nitroglycerin Consumption (Table 2) The frequency of anginal pain was significantly reduced by PROPRA (7.0 ± 2.5 anginal pains/week) and by COMB (9.9 ± 2.9) when compared either with PLAC (21.0 + 6.4) or ISO (16.8 ± 4.3 anginal pains/week). There was no difference between PLAC and ISO. The number of nitroglycerin tablets consumed was also reduced significantly by the propranolol-containing regimens.
Resting Heart Rate and Blood Pressure (Table 3) Heart rate at rest was slower on propranololcontaining regimens as compared with placebo or isosorbide or both regimens. The treatments did not affect systolic blood Figure 1 shows the effect of the various treatments on the capacity of patients to perform the multistage exercise test. Regardless of the treatment given, these patients were severely limited by their angina. As a group they were able to exercise only into the second stage of the treadmill test which is considerably less exercise than can be performed by age-matched normals.7 Although the treatments were found to affect the endurance time (F 3.5, P < 0.05), the individual differences were very small. The only significant difference among the treatments was found between COMB (5 min, 19±26 see) and ISO (4 min, 19 ± 30 sec). The therapeutic importance of this difference appears doubtful, however, because a small decrease in endurance time occurred with ISO when it was compared with PLAC (4 min, 29 + 26 sec) or PROPRA (4 min, 47 + 26 see).
Ten patients performed better on PROPRA and 11 did worse as compared with their performance on PLAC. Fourteen patients As can be seen in table 4, the treatments affected both maximal heart rate (F 24.21, P <0.001) and maximal systolic pressure (F 3.2, P <0.05) with no effect on maximal diastolic blood pressure (F 2.4, P not significant). However, no individual differences between treatments could be found for maximal systolic blood pressure. Significant slowing of the maximal heart rate was obtained with propranolol-containing regimens when compared with either PLAC or ISO. The product of maximal heart rate and maximal systolic blood pressure was also significantly reduced by PROPRA and by COMB. It decreased from 22.1 + 1.2 x 103 on PLAC to 17.3 + 0.7 x 103 on PROPRA and 17.0 + 0.6 x 103 on COMB of drugs (F 17.2, P <0.001).
ST-Segment Changes
Although the treatments affected the maximal ST-segment depression during and after exercise (F 4.0, P <0.05), no significant differences were found among individual treatments. The ST-segment changes on propranolol-containing regimens tended to be smaller, but these were attained when the maximal heart rate showed a mean reduction of 21 beats/min, or 16% decrease in maximal heart rate.
Discussion
Propranolol has pharmacologic actions that may be either beneficial or harrnful to patients with angina pectoris. Beneficial effects could result from a reduction in myocardial oxygen requirements brought about by a decrease in heart rate,10 a decrease in the velocity of myocardial fiber shortening,'1 and a reduction in arterial pressure.'2 Harmful effects of propranolol might occur, however, as an effect of depression of myocardial contractility, possibly leading to heart failure in those patients with impaired myocardial function. Furthermore, these latter authors were unable to confirm the beneficial effects of propranolol when compared to placebo. The present study confirms the symptomatic improvement in angina patients on propranolol, while isosorbide dinitrate was found to be of no value when compared to placebo and no synergism could be demonstrated between propranolol and isosorbide dinitrate. In contrast to the paper by Battock and associates, who studied 10 patients, no objective improvement in exercise performance was observed in our study population.
In agreement with Gianelly and co-workers,23 ischemic ST-segment depression was not prevented by propranolol and developed at lower heart rates. These authors suggested that significant myocardial ischemia still occurred at comparable levels of exercise, but that chest pain was delayed by propranolol. They were unable to use urinary catecholamines as an indicator of those patients who would improve on propranolol. In this study, the presence or absence of healed myocardial infarction also appeared to be of no value in predicting favorable responses to propranolol.
In long-term follow-up studies, Amsterdam and associates24 suggested that propranolol decreased mortality in angina patients, but Zeft and co-workers25 found no apparent reduction in mortality and suggested that propranolol did not affect the natural course of symptomatic coronary artery disease. Since our study was initiated, four of our patients experienced significant progression of their coronary artery disease while receiving propranolol. Two sustained myocardial infarctions, and one of these died suddenly at home after an apparently uneventful recovery. Two other patients needed other measures for symptomatic control of their angina: one underwent a myocardial revascularization operation, and the other had a carotid sinus stimulator implanted.
The ideal agent for the treatment of patients with angina pectoris should reduce symptoms, improve exercise performance, eliminate ischemic changes in the exercise electrocardiogram, and improve longevity. Our data and a critical review of the literature suggest that propranolol is not that agent and that isosorbide dinitrate appears to be not much better than a placebo. However, in carefully selected patients propranolol can be used in the symptomatic treatment of angina pectoris.
